ESAB vs RTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ESAB exhibits strong operational health with a Piotroski F-Score of 7/9 and a healthy balance sheet (Debt/Equity 0.61), yet it faces a significant valuation disconnect. While the company has a remarkable track record of beating earnings estimates for 16 consecutive quarters, the current price of $101.28 trades at a substantial premium to its Graham Number ($57.36) and Intrinsic Value ($28.70). The outlook is conflicted: analysts maintain a 'strong_buy' with a target of $136.56, but technical trends are bearish (0/100) and YoY earnings growth has plummeted by 31.6%.
RTX exhibits stable financial health with a Piotroski F-Score of 5/9, yet it is trading at a severe premium compared to its Graham Number ($73.73) and Intrinsic Value ($96.67). While the company boasts an exceptional track record of earnings beats over 25 quarters and solid revenue growth, the valuation is stretched with a PEG ratio of 2.75. This fundamental overvaluation is compounded by bearish insider sentiment and a weak technical trend, suggesting that while the business is strong, the stock price is currently decoupled from its deterministic value.
Compare Another Pair
Related Comparisons
ESAB vs RTX: Head-to-Head Comparison
This page compares ESAB Corporation (ESAB) and RTX Corporation (RTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.